Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study.

Benza RL, Raina A, Gupta H, Murali S, Burden A, Zastrow MS, Park MH, Simon MA.

Pulm Circ. 2018 Jan-Mar;8(1):2045893217741480. doi: 10.1177/2045893217741480. Epub 2017 Oct 24.

2.

Sildenafil add-on therapy in paediatric pulmonary arterial hypertension, experiences of a national referral centre.

Douwes JM, Roofthooft MT, Van Loon RL, Ploegstra MJ, Bartelds B, Hillege HL, Berger RM.

Heart. 2014 Feb;100(3):224-30. doi: 10.1136/heartjnl-2013-304895.

PMID:
24390161
3.

Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost.

Han X, Zhang Y, Dong L, Fang L, Chai Y, Niu M, Yu Y, Liu L, Yang X, Qu S, Li S.

Respir Care. 2017 Apr;62(4):489-496. doi: 10.4187/respcare.05280. Epub 2017 Jan 24.

4.

Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial.

McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W.

J Am Coll Cardiol. 2010 May 4;55(18):1915-22. doi: 10.1016/j.jacc.2010.01.027.

5.

Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.

Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, Hassoun PM.

Eur Respir J. 2007 Mar;29(3):469-75. Epub 2006 Nov 1.

6.

Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology.

D'Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, Correra A, Scognamiglio G, Russo MG, Calabrò R.

Int J Cardiol. 2012 Mar 22;155(3):378-82. doi: 10.1016/j.ijcard.2010.10.051. Epub 2010 Nov 16.

PMID:
21081251
7.
8.

Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.

Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ.

J Am Coll Cardiol. 2006 Oct 3;48(7):1433-7. Epub 2006 Sep 14.

9.

[Sildenafil therapy for pulmonary hypertension: a prospective study].

Lu XL, Xiong CM, Shan GL, Liu ZH, Ni XH, Cheng XS, Gu Q, Zhao ZH, Zeng WJ, Zhu F, He JG.

Zhonghua Jie He He Hu Xi Za Zhi. 2011 Jun;34(6):419-23. Chinese.

PMID:
21781512
10.

Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension.

Barst RJ, Oudiz RJ, Beardsworth A, Brundage BH, Simonneau G, Ghofrani HA, Sundin DP, Galiè N; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group.

J Heart Lung Transplant. 2011 Jun;30(6):632-43. doi: 10.1016/j.healun.2010.11.009. Epub 2011 Jan 21.

PMID:
21256048
11.

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.

Tapson VF, Torres F, Kermeen F, Keogh AM, Allen RP, Frantz RP, Badesch DB, Frost AE, Shapiro SM, Laliberte K, Sigman J, Arneson C, Galiè N.

Chest. 2012 Dec;142(6):1383-1390. doi: 10.1378/chest.11-2212.

PMID:
22628490
12.

Effect of dual pulmonary vasodilator therapy in pulmonary arterial hypertension associated with congenital heart disease: a retrospective analysis.

Monfredi O, Heward E, Griffiths L, Condliffe R, Mahadevan VS.

Open Heart. 2016 Apr 15;3(1):e000399. doi: 10.1136/openhrt-2016-000399. eCollection 2016.

13.

Early decline in six-minute walk distance from the time of diagnosis predicts clinical worsening in pulmonary arterial hypertension.

Huang J, Mehta S, Mura M.

Respiration. 2015;89(5):365-73. doi: 10.1159/000370124. Epub 2015 Mar 13.

14.

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension.

McLaughlin V, Channick RN, Ghofrani HA, Lemarié JC, Naeije R, Packer M, Souza R, Tapson VF, Tolson J, Al Hiti H, Meyer G, Hoeper MM.

Eur Respir J. 2015 Aug;46(2):405-13. doi: 10.1183/13993003.02044-2014. Epub 2015 Jun 25.

15.

Pulmonary Arterial Hypertension: Screening, Management, and Treatment [Internet].

McCrory DC, Coeytaux RR, Schmit KM, Kraft B, Kosinski AS, Mingo AM, Vann LM, Gilstrap DL, Hargett CW, Lugogo NL, Heidenfelder BL, Posey R, Irvine RJ, Wing L, Pendergast K, Dolor RJ.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2013 Apr.

16.
17.

Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in Pulmonary Arterial Hypertension.

Amin A, Mohamadifar A, Taghavi S, Naderi N, Sadeghi H.

Res Cardiovasc Med. 2015 Aug 1;4(3):e26487. doi: 10.5812/cardiovascmed.26487v2. eCollection 2015 Aug.

18.

Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension.

Hoeper MM, Faulenbach C, Golpon H, Winkler J, Welte T, Niedermeyer J.

Eur Respir J. 2004 Dec;24(6):1007-10.

19.

Metformin added to bosentan therapy in patients with pulmonary arterial hypertension associated with congenital heart defects: a pilot study.

Liao S, Li D, Hui Z, McLachlan CS, Zhang Y.

ERJ Open Res. 2018 Aug 22;4(3). pii: 00060-2018. doi: 10.1183/23120541.00060-2018. eCollection 2018 Jul.

20.

Ambrisentan response in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) - A subgroup analysis of the ARIES-E clinical trial.

Fischer A, Denton CP, Matucci-Cerinic M, Gillies H, Blair C, Tislow J, Nathan SD.

Respir Med. 2016 Aug;117:254-63. doi: 10.1016/j.rmed.2016.06.018. Epub 2016 Jun 29.

Supplemental Content

Support Center